Biodesix Inks Deal with Bruker for Mass Spec Support; Closes on $8.8M in Series D Financing | GenomeWeb

NEW YORK (GenomeWeb News) – Biodesix said today it has entered a collaborative agreement with Bruker Daltonics to support its VeriStrat diagnostic test as well as future tests based on MALDI-TOF mass spectrometry.

A serum protein test for identifying non-small cell lung cancer patients likely to respond to various therapies, Veristrat runs on Biodesix's MALDI-TOF-based ProTS platform, which uses Bruker Autoflex and Ultraflextreme instruments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.